MedTrace Logo

Lab Research Using Mini-tumors to Study Prostate Cancer Treatments

NCT07004582 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 600

Last updated 2026-04-23

No results posted yet for this study

Summary

For men with an aggressive form of prostate cancer, finding the right and effective treatment right away is challenging. Many of these men face a high risk of cancer recurrence: about half experience a relapse after surgery, and more than a third after undergoing radiation therapy. Men with metastatic prostate cancer have particularly poor prognoses, with a five-year survival rate of only 30% to 50%. In short, it is difficult to predict which treatment, or combination of treatments, will lead to longer survival for this group of men with aggressive (metastatic) prostate cancer.

In the laboratory, it is possible to grow small samples of tumors into 3D mini-tumors. These mini-tumors retain the characteristics of the patient's original tumor tissue. Various treatments can be tested on these 3D mini-tumors to determine which therapy is most effective for each individual case. There are currently two techniques available for creating these 3D mini-tumors in the lab. In this project, we aim to investigate which of these two techniques works best in order to test and personalize treatments.

Conditions

Interventions

PROCEDURE

HDR brachytherapy

High dose rate (HDR) brachytherapy for the treatment of high-risk or recurrent prostate cancer

DIAGNOSTIC_TEST

Diagnostic biopsy

Transperineal prostate biopsies guided with transrectal ultrasound for the diagnosis of (recurrent) prostate cancer

Sponsors & Collaborators

  • Zuyderland Medical Centre

    collaborator OTHER

  • Maastricht University Medical Center

    collaborator OTHER

  • Maastricht Radiation Oncology

    lead OTHER

Principal Investigators

  • Evert J Van Limbergen, PhD, MD · Maastricht Radiation Oncology

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-03-15
Primary Completion
2031-09-30
Completion
2031-12-30

Countries

  • Netherlands

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07004582 on ClinicalTrials.gov